Augmedix (NASDAQ:AUGX) Coverage Initiated by Analysts at B. Riley

B. Riley assumed coverage on shares of Augmedix (NASDAQ:AUGXFree Report) in a report released on Wednesday, MarketBeat.com reports. The brokerage issued a buy rating and a $5.50 price objective on the stock.

AUGX has been the topic of a number of other reports. Evercore ISI cut their price objective on Augmedix from $6.50 to $4.50 and set an in-line rating on the stock in a research note on Tuesday, March 19th. Maxim Group dropped their price target on Augmedix from $6.50 to $5.00 and set a buy rating on the stock in a research report on Tuesday, March 19th.

Get Our Latest Stock Report on Augmedix

Augmedix Stock Up 4.0 %

Shares of AUGX stock opened at $4.18 on Wednesday. The stock’s 50 day simple moving average is $4.21 and its 200 day simple moving average is $4.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.41 and a current ratio of 2.41. Augmedix has a twelve month low of $1.50 and a twelve month high of $6.25. The company has a market capitalization of $203.73 million, a price-to-earnings ratio of -9.29 and a beta of -0.16.

Insiders Place Their Bets

In other Augmedix news, insider Ian Shakil sold 31,994 shares of Augmedix stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $4.06, for a total value of $129,895.64. Following the transaction, the insider now directly owns 187,666 shares of the company’s stock, valued at approximately $761,923.96. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 10.97% of the company’s stock.

Institutional Trading of Augmedix

Several institutional investors have recently modified their holdings of the company. Perkins Capital Management Inc. grew its holdings in shares of Augmedix by 5.3% during the 4th quarter. Perkins Capital Management Inc. now owns 1,464,568 shares of the company’s stock worth $8,568,000 after purchasing an additional 73,475 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Augmedix by 8.1% during the 4th quarter. Vanguard Group Inc. now owns 1,122,890 shares of the company’s stock worth $6,569,000 after purchasing an additional 84,294 shares in the last quarter. Parkman Healthcare Partners LLC grew its holdings in shares of Augmedix by 170.1% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,015,814 shares of the company’s stock worth $5,943,000 after purchasing an additional 639,732 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Augmedix by 292.0% during the 4th quarter. Russell Investments Group Ltd. now owns 891,077 shares of the company’s stock worth $5,213,000 after purchasing an additional 663,778 shares in the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of Augmedix during the 3rd quarter worth approximately $2,237,000. Institutional investors and hedge funds own 87.11% of the company’s stock.

About Augmedix

(Get Free Report)

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.

Read More

Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with MarketBeat.com's FREE daily email newsletter.